A mass spectrometer weighs a molecule; it does not read it from one end to the other. That distinction is the single most consequential limitation of a routine identity check, and it is why a certificate reporting a correct mass has confirmed composition without confirming sequence. For most work the mass check is sufficient. For work where residue order carries the result, it is not, and knowing which situation you are in is the whole point.
The errors a mass check cannot see
Mass is a sum, and sums are indifferent to order. Any error that rearranges the same atoms without adding or removing any is invisible to a weighing, however precise the instrument.
| Error | Mass change | Detectable by mass? |
|---|---|---|
| A residue deleted or truncated | Large | Yes, easily |
| An oxidation or a deamidation | Small but definite | Yes, with adequate resolution |
| Two residues swapped in position | None | No |
| Leucine in place of isoleucine | None — identical formula | No, not even in principle |
| A D-residue in place of an L-residue | None | No |
| A bridge closed between the wrong pair | None | No |
The lower four rows are the uncomfortable ones. A swapped pair of residues produces a molecule with the same formula, the same mass and a different biology, and it will pass an identity check and a purity check together. Mass spectrometry is excellent at what it does; this simply is not what it does.
Why are leucine and isoleucine indistinguishable?
Because they are structural isomers with the identical molecular formula — the same atoms connected differently. No mass measurement at any resolution can separate them, since there is no mass difference to resolve. The same applies to any isomeric pair. Reading a sequence as letters makes this concrete: a peptide written with Leu at one position and Ile at another weighs exactly as much as the version with them exchanged, and so does every other permutation of the two. Distinguishing them requires fragmentation or a chemical method that works residue by residue.
What does tandem MS add?
It breaks the molecule and weighs the pieces, which converts a question about order into a series of questions about mass. The backbone fragments preferentially at the amide bonds, generating a ladder of pieces that each differ from the next by one residue. Subtracting adjacent masses in that ladder gives the residue at each position, read sequentially — so the sequence is reconstructed from differences rather than measured directly.
This catches a swapped pair, because the swap changes where each mass increment appears in the ladder even though the total is unchanged. It still cannot separate leucine from isoleucine, since the increment for each is the same number, and it does not distinguish a D-residue from an L-residue. The method is a large improvement and not a complete answer.
What does Edman degradation do differently?
It removes one residue at a time from the N-terminus and identifies each as it comes off, chemically rather than by mass. That makes it a genuine sequential read, and historically it was the method that established sequences before mass spectrometry was routine. Its limits are practical: it works from one end only, it is slow, it needs a free N-terminus — so an acetylated or otherwise capped peptide is immediately out of scope — and it struggles with modified residues. For a short linear peptide with a free terminus it is informative. For a cyclic peptide there is no terminus to start from at all.
When sequence confirmation is worth the cost
Rarely, and the honest position is that most routine work does not need it. Three situations change that.
The result depends on a specific residue. If the experiment is about a particular position — a substitution, a motif, a modification site — then the one thing a mass check cannot verify is the thing the experiment is about.
A reference standard is being established. Material that other measurements will be compared against carries more weight than a single experiment, and the cost of confirming it is amortised across everything that follows.
Results disagree between lots. Where two lots of the same compound both pass identity and purity but behave differently, sequence is one of the few explanations the standard panel cannot exclude. It is not the first thing to check — net peptide content differing between lots explains far more lot-to-lot variation and is much cheaper to check — but it is on the list.
What should a routine certificate be expected to carry?
Identity by mass, purity by chromatography, content, and the safety attributes — which is what a good certificate does carry. Sequencing is not a routine release test for research peptides and its absence is not a deficiency. What is a deficiency is a document that implies more than it establishes: a line reading "Sequence: confirmed" with mass spectrometry as the stated method is overclaiming, because that method confirmed composition. Knowing which question your certificate answered is more useful than wishing it had answered a different one. Our lot documents are searchable on the lot verification page.
Does high purity make a sequence error less likely?
Only indirectly, and the reasoning is worth being careful with. A high purity figure says the preparation is chromatographically homogeneous — one dominant species rather than a mixture. A systematic synthesis error produces exactly that: a single wrong product, cleanly made, at high purity. In that scenario purity is high precisely because the error was consistent. Purity constrains how much of something else is present; it says nothing about whether the main component is right. The synthesis route is where that risk originates, and a well-controlled route is the real mitigation.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
